Watch TCRX. Know when insiders buy.
One email the day a filing lands. Free.
TCRX
TScan Therapeutics, Inc.
0.34
−0.01 −2.58%
USD · close Sep 25
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
29
FLAG · shorts 29
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $8.2MP/E —DIV YIELD —FCF YIELD -1452.85%REV TTM $7.1M +2.2%NET INCOME −$117.7MNET CASH $67.4M52W 0.31 – 2.52SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $1.1M | −65.8% | — | −$30.5M | −$30.4M | — | -0.23 | −$27.5M | $493K | −$28M | Aug 12 |
| Q1 2026 · Mar 31 | $982K | −54.8% | — | −$29.1M | −$28.7M | — | -0.22 | −$24.3M | $70K | −$24.3M | May 6 |
| Q4 2025 · Dec 31derived | $2.6M | +286.0% | — | −$23.9M | −$23M | — | -0.18 | −$32M | $171K | −$32.2M | Mar 4 |
| Q3 2025 · Sep 30 | $2.5M | +139.4% | — | −$37.1M | −$35.7M | — | -0.28 | −$32.5M | $1.4M | −$33.9M | Nov 12 |
| Q2 2025 · Jun 30 | $3.1M | +473.9% | — | −$38.7M | −$37M | — | -0.28 | −$33.3M | $1.3M | −$34.5M | Aug 12 |
| Q1 2025 · Mar 31 | $2.2M | +283.6% | — | −$36.3M | −$34.1M | — | -0.26 | −$37.6M | $1.5M | −$39.1M | May 6 |
| Q4 2024 · Dec 31derived | $665K | −90.8% | — | −$36.7M | −$35.8M | — | -0.30 | −$27.4M | $888K | −$28.3M | Mar 4 |
| Q3 2024 · Sep 30 | $1M | −73.0% | — | −$32.6M | −$29.9M | — | -0.25 | −$27.9M | $1.4M | −$29.3M | Nov 12 |
| Q2 2024 · Jun 30 | $536K | — | — | −$34.1M | −$31.7M | — | -0.28 | −$26.2M | $862K | −$27.1M | Aug 12 |
| Q1 2024 · Mar 31 | $566K | — | — | −$31.4M | −$30.1M | — | -0.32 | −$29.3M | $705K | −$30M | May 6 |
| Q4 2023 · Dec 31derived | $7.2M | — | — | −$21.4M | −$19.6M | — | -0.11 | −$23.8M | $469K | −$24.2M | Mar 5 |
| Q3 2023 · Sep 30 | $3.9M | — | — | −$24.7M | −$23M | — | -0.24 | $8M | $1.4M | $6.6M | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $10.3M | — | −$135.8M | −$129.8M | -1256.8% | -1.00 | −$135.3M | $4.4M | −$139.7M | — | — |
| FY2024 · to Dec 31 | $2.8M | — | −$134.8M | −$127.5M | -4527.7% | -1.14 | −$110.8M | $3.8M | −$114.6M | — | — |
| FY2023 · to Dec 31 | $21M | — | −$93.5M | −$89.2M | -423.9% | -1.36 | −$61.4M | $3.1M | −$64.5M | — | — |
| FY2022 · to Dec 31 | $13.5M | — | −$66.6M | −$66.2M | -489.3% | -2.75 | −$66.5M | $4.2M | −$70.7M | — | — |
| FY2021 · to Dec 31 | $10.1M | — | −$48.6M | −$48.6M | -479.5% | -4.17 | −$48.7M | $9.9M | −$58.6M | — | — |
| FY2020 · to Dec 31 | $1.1M | — | −$26.2M | −$26.1M | -2408.0% | -28.52 | −$3M | $4.2M | −$7.3M | — | — |
Every number comes from TScan Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.